Manufacturers

Valuing potential cures: An examination of ICER’s approach to assessing high-impact single and short-term therapies

Manufacturers

Q&A: The evolution of the cell and gene therapy field

Manufacturers

Recap Asembia 2023: Our impactful contributions to the premier specialty pharmacy conference

Manufacturers

Three opportunities and three challenges in the cell and gene therapy market

Manufacturers

Recap AMCP 2023: Our thought leadership in action

Manufacturers

Navigating reimbursement and access challenges for novel cell and gene therapies

Manufacturers

Webinar slides: Navigating Reimbursement and Access Challenges for Novel Cell and Gene Therapies

Medicaid Best Price and Its Implications on Cell and Gene Therapy Products

Manufacturers

What manufacturers need to know about reimbursement and patient support for cell and gene therapies

Emerging Gene Therapies for Hemophilia in the United States—Value Drivers in a Crystal Ball

Tumor-Agnostic Therapy Assessment: Following Regulatory Approval, What Challenges Exist for HTAs?

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part One

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part Two

Manufacturers

Rethink: Payer Strategies for Commercializing Cell and Gene Therapies

Achieving Market Access Across the Globe for CGTs